Tag: Celgene

Evotec and Celgene Expand its Alliance

Evotec SE announced that its strategic alliance with Celgene Corporation has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the col...

Celgene Announced FDA and EMA Accepted Applications for Ozanimod

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for ozanimod for the treatment of people with relapsing forms of multipl...

FDA Accepted BLA for Celgene’s Erythroid Maturation Agent

celgene
Celgene Corporation and Acceleron Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics License Application (BLA) for luspatercept, an investigational...

Celgene Received FDA Approval for REVLIMID

Celgene Corporation announced the U.S. Food and Drug Administration (FDA) approved REVLIMID® (lenalidomide) in combination with a rituximab product (R²) for the treatment of adult patients with previo...

BMS Selling $19bn of Bonds to Buy Celgene

The U.S. drugmaker Bristol-Myers Squibb (BMS) is preparing to place $19 billion in bonds to fund the acquisition of the rival company Celgene Corp in the largest bond issue since the beginning of 2019...

Celgene and MSAA Launched New MS Campaign

Celgene Corporation and the Multiple Sclerosis Association of America (MSAA) announced the launch of a new campaign, MS MindShift: A New View of MS, a national initiative that provides new perspective...

European Commission Approved Celgene Revlimid and Imnovid

Celgene Corporation announced that the European Commission (EC) has approved two new triplet regimens based on Celgene’s proprietary IMiD treatments, REVLIMID (lenalidomide) and IMNOVID (pomalidomide)...

Bristol-Myers Squibb Shareholders Approve the Acquisition of Celgene

Bristol-Myers Squibb shareholders approved the pharmaceutical giant’s $74 billion acquisition of cancer drugmaker Celgene. The deal, announced in January, was a hard sell to Bristol shareholders from ...

Two Celgene Meds Received CHMP Positive Opinion

Celgene Corporation, announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for two triplet regimens based on Celgene’...

Celgene Sumitted NDA for Ozanimod

Celgene Corporation announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of mult...

Celgene Partners with AI Drug Discovery Company

Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered a three-year AI drug discovery partnership with leading biopharma company Ce...

BMS Urges Shareholders to Vote FOR Acquisition of Celgene

Bristol-Myers Squibb Company today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with its previously announced definitive merger agreement with Celg...

Celgene Cancer Treatment Therapy Not Reach Endpoint

Top-line results announced from the international Phase 3 study evaluating adjuvant therapy with ABRAXANE in combination with gemcitabine vs. gemcitabine alone for patients with surgically resected pa...

Celgene Submitted MAA for Ozanimod

Celgene Corporation today announced that the Company has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for ozanimod for the treatment of adults with relapsing-...

Priority Review for Celgene Myelofibrosis Med

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for fedratinib and granted a Priority Review. Fedratinib is a high...

BMS Responded to Starboard Statement against Merge with Celgene

Bristol-Myers Squibb Company issued the following statement in response to a letter from Starboard Value (“Starboard”): "Bristol-Myers Squibb welcomes the opinions of all of its stockholders and wi...